Johnson & Johnson (J&J), one of the maker of Covid-19 vaccines, had net income of $4.74 billion in the fourth quarter of 2021, 172.5% higher than the gain of $1.74 billion verified in the same period of 2020, according to balance sheet published this Tuesday.
Adjusting for this, J&J’s earnings per share between October and December were $2.13, slightly above the forecast of analysts polled by FactSet of $2.12.
The US pharmaceutical group’s revenue grew 10.4% year-on-year in the fourth quarter to $24.8 billion, but was below the FactSet consensus of $25.3 billion.
The post Johnson & Johnson Increases Profit, But Revenue Disappoints in Q4 appeared first on ISTOÉ DINHEIRO.
#Johnson #Johnson #expands #profit #revenue #disappoints #4th #quarter #ISTOÉ #DINHEIRO